Study type: In vitro · Status: Verified against declared source

LL-37 boosts immunosuppressive function of placenta-derived mesenchymal stromal cells.

Stem cell research & therapy · 2016

Study scale: Not reported

Product or molecular entity relationships

LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Despite promising, the results obtained by MSC treatment of GvHD are still heterogeneous, and there is much room for improvement [4, 5].

Methods

Mesenchymal stem cells (MSCs) have riveted the attention of the scientific community, due to their surprisingly effective ability to suppress immune response.

Scale or participants

Not reported in the reviewed source.

Key findings

Although promising for graft-versus-host disease (GvHD) treatment, MSC therapy still faces important challenges.

Limitations and uncertainty

Despite promising, the results obtained by MSC treatment of GvHD are still heterogeneous, and there is much room for improvement [4, 5].

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.